Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and ...

Early prophylaxis reduces bone loss in haemophilia, while delayed or absent treatment increases osteoporosis risk.

Prophylactic medication after ileocaecal resection in patients with Crohn's disease reduces long-term rates of severe endoscopic recurrence and endoscopic or radiologic recurrence, serving as a ...

If approved, marstacimab would be the first non-factor prophylactic treatment indicated for pediatric patients aged 6 to 11 years with hemophilia B.

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

The introduction of urate-lowering therapy can affect the risk for gout flares, with fewer flares observed when less intensive treatment and flare prophylaxis were used. The introduction of ...